Autosomal Dominant Polycystic
Kidney Disease
ADPKD is one of the most common hereditary kidney disorders — and one of the most manageable when caught early and overseen by a specialist.
What Is ADPKD?
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic condition in which clusters of fluid-filled cysts develop progressively within the kidneys. Over time, these cysts multiply and enlarge, causing the kidneys to expand significantly in size — though not in function. As the condition advances, kidney function gradually declines.
ADPKD affects an estimated 5 to 10 people per 10,000 births, placing it among the more common hereditary disorders worldwide. It is not a lifestyle condition, not an autoimmune disease, and not infectious — it is a consequence of specific inherited gene mutations that alter the microscopic architecture of the kidneys.
How Is It Inherited?
ADPKD follows a clear genetic pattern. The condition is passed down through families, though not every family member will be affected.
In approximately 80% of cases, the relevant mutation occurs on chromosome 16. Individuals with this variant tend to experience a more challenging disease course. The second most common mutation involves chromosome 4 and is generally associated with a milder progression. A smaller subset of cases involves mutations in other genes.
In some instances, ADPKD arises spontaneously — a new mutation with no family history — though it can then be passed on to future generations.
Risk Factors for Faster Progression
Not everyone with ADPKD progresses at the same rate. Several factors are associated with a faster decline in kidney function:
- Chromosome 16 mutation — this genetic variant carries a higher risk of accelerated progression compared to chromosome 4 mutations
- Family history of early kidney failure — a hereditary pattern of premature total kidney failure raises individual risk
- Male sex — men tend to experience a more aggressive disease course than women
- Enlarged kidneys — kidney volume, measured precisely by MRI, is a key prognostic indicator; larger kidneys predict a less favourable outlook
- Proteinuria — the presence of protein in the urine signals additional stress on the kidneys
- History of cyst bleeding — prior episodes of cystic haemorrhage are associated with faster progression
- High urinary sodium excretion — elevated salt in the urine correlates with accelerated disease
- Co-existing kidney conditions — hypertension, diabetes, or glomerulonephritis that are poorly controlled compound the risk significantly
- Nephrotoxic medications — certain painkillers (NSAIDs such as ibuprofen, diclofenac, naproxen, celecoxib, etoricoxib) can harm kidney function and should be avoided unless specifically cleared by your specialist
- Nephrotoxic imaging agents — radio-contrast agents used in CT scans carry risk; this should be weighed carefully and managed proactively
Symptoms
ADPKD often develops silently in its early stages. Many patients are diagnosed incidentally — through a scan performed for an unrelated reason, or during screening prompted by a family history of the condition.
As the disease progresses, symptoms become more apparent.
Abdominal fullness and discomfort
Enlarging kidneys press against surrounding organs, causing a sensation of bloatedness or chronic discomfort.
Flank pain
Cyst rupture can cause acute pain and blood in the urine. Chronic pain may also arise from the kidney's stretched outer lining (capsule), or from pressure on the ureter and blood vessels.
High blood pressure
Hypertension frequently accompanies ADPKD and becomes increasingly difficult to control as the disease advances.
Symptoms of declining kidney function
Fatigue, itchiness, nausea, reduced appetite, leg swelling, and shortness of breath may develop as kidney function falls.
Beyond the kidneys
ADPKD can affect other organs. Cysts may form in the liver, pancreas, and epididymis. Cerebral artery aneurysms can develop, carrying risk of rupture. Gastrointestinal diverticula, abdominal hernias, and cardiac valve abnormalities have also been associated with the condition.
Diagnosis
Imaging
Ultrasound, CT, or MRI scans can reveal the presence of cysts in the kidneys. A finding of ten or more cysts in each kidney — particularly alongside kidney enlargement and cysts in the liver — is strongly indicative of ADPKD. MRI is especially valuable for precisely measuring total kidney volume, an important marker of disease severity.
Family history
A documented family history simplifies the diagnostic picture considerably and guides how aggressively screening should be pursued.
Genetic testing
Genetic testing is not routine given its cost and limited availability, but it plays an important role in specific situations: confirming a diagnosis when imaging is inconclusive, evaluating potential living kidney donors within affected families, and informing family planning decisions. The emotional and psychological implications of early genetic diagnosis deserve careful consideration, and informed consent is essential before proceeding.
Treatment and Management
There is currently no cure for ADPKD — it is a genetic condition. Management is therefore focused on slowing progression, protecting kidney function, and maintaining quality of life for as long as possible.
Tolvaptan
The only approved medication that has demonstrated meaningful reduction in kidney enlargement and disease progression. Its use is governed by availability, cost, insurance coverage, and tolerability — regular monitoring of sodium levels and liver enzymes is required. Patients at high risk of progression who are candidates for this treatment should discuss it with their nephrologist. Those who cannot access tolvaptan are generally advised to maintain high fluid intake — approximately 3 to 3.5 litres of water per day.
Blood pressure control
Central to protecting the kidneys. Target blood pressure in ADPKD — particularly in younger patients — is set lower than in other forms of chronic kidney disease. Antiproteinuric medications (which also lower blood pressure) are commonly prescribed for their additional kidney-protective effects.
Comprehensive management of co-existing conditions
Hypertension, diabetes, and other kidney-affecting illnesses must be well controlled. Poorly managed comorbidities accelerate decline.
Kidney replacement therapy
For patients who progress to end-stage kidney disease, kidney transplantation is the preferred option. Where transplantation is not possible, haemodialysis is prioritised over peritoneal dialysis, as enlarged kidneys may limit abdominal space for the latter.
Psychosocial support
Living with a hereditary, progressive condition carries an emotional weight that should not be underestimated. Connecting with a psychologist, medical social worker, or a patient advocacy organisation can provide meaningful support alongside clinical care.
Ongoing research
Gene therapy and targeted treatments continue to evolve, offering hope for improved management strategies in the years ahead.
Understanding Polycystic Kidney Disease — A Specialist's Perspective
Dr. Francisco Salcido-Ochoa wrote about ADPKD in a guest column for Medical Channel Asia, covering the genetics, symptoms, progression risk factors, and management of the condition in accessible detail.
Book a Consultation
If you have been diagnosed with ADPKD, have a family history of polycystic kidney disease, or would like specialist evaluation, Dr. Francisco Salcido-Ochoa is available for consultation.
This page is for general informational purposes only and does not constitute medical advice. ADPKD is a complex condition that requires specialist evaluation. If you have a family history of polycystic kidney disease or have been told you may be at risk, please consult a qualified nephrologist.